0.730
-0.20 (-21.76%)
| 前收盘价格 | 0.933 |
| 收盘价格 | 0.780 |
| 成交量 | 1,118,599 |
| 平均成交量 (3个月) | 602,701 |
| 市值 | 16,334,793 |
| 预期市盈率 (P/E Forward) | 0.520 |
| 价格/销量 (P/S) | 3.16 |
| 股市价格/股市净资产 (P/B) | 0.240 |
| 52周波幅 | |
| 利润日期 | 13 May 2026 |
| 稀释每股收益 (EPS TTM) | -5.76 |
| 总债务/股东权益 (D/E MRQ) | 1.47% |
| 流动比率 (MRQ) | 0.370 |
| 营业现金流 (OCF TTM) | -23.55 M |
| 杠杆自由现金流 (LFCF TTM) | 15.85 M |
| 资产报酬率 (ROA TTM) | -25.32% |
| 股东权益报酬率 (ROE TTM) | -60.53% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Citius Pharmaceuticals, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 3.5 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.50 |
|
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 4.41% |
| 机构持股比例 | 5.69% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Heights Capital Management, Inc | 31 Dec 2025 | 799,934 |
| Asset Advisory Group, Inc. | 31 Mar 2026 | 59,011 |
| Arkadios Wealth Advisors | 31 Dec 2025 | 20,000 |
| 52周波幅 | ||
| 中 | 6.00 (721.92%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| D. Boral Capital | 11 Mar 2026 | 6.00 (721.92%) | 购买 | 0.910 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合